Lexicon Pharmaceuticals Inc [NASDAQ: LXRX] jumped around 0.13 points on Thursday, while shares priced at $1.22 at the close of the session, up 11.93%.
Compared to the average trading volume of 3.22M shares, LXRX reached a trading volume of 5611491 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Lexicon Pharmaceuticals Inc [LXRX]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for LXRX shares is $2.75 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on LXRX stock is a recommendation set at 1.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Leerink Partners have made an estimate for Lexicon Pharmaceuticals Inc shares, keeping their opinion on the stock as Market Perform, with their previous recommendation back on March 05, 2025. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on June 17, 2024, representing the official price target for Lexicon Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $5, while Leerink Partners analysts kept a Outperform rating on LXRX stock.
The Price to Book ratio for the last quarter was 3.43, with the Price to Cash per share for the same quarter was set at 0.38.
How has LXRX stock performed recently?
Lexicon Pharmaceuticals Inc [LXRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 9.91. With this latest performance, LXRX shares gained by 5.17% in over the last four-week period, additionally plugging by 241.26% over the last 6 months – not to mention a rise of 65.20% in the past year of trading.
Lexicon Pharmaceuticals Inc [LXRX]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Lexicon Pharmaceuticals Inc [LXRX] shares currently have an operating margin of -187.35% and a Gross Margin at 98.14%. Lexicon Pharmaceuticals Inc’s Net Margin is presently recorded at -206.43%.
Lexicon Pharmaceuticals Inc (LXRX) Capital Structure & Debt Analysis
According to recent financial data for Lexicon Pharmaceuticals Inc. ( LXRX), the Return on Equity (ROE) stands at -65.30%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -40.28%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Lexicon Pharmaceuticals Inc’s Return on Invested Capital (ROIC) is -63.49%, showcasing its effectiveness in deploying capital for earnings.
Lexicon Pharmaceuticals Inc (LXRX) Efficiency & Liquidity Metrics
Based on Lexicon Pharmaceuticals Inc’s (LXRX) latest financial statements, the Debt-to-Equity Ratio is 0.47%, indicating its reliance on debt financing relative to shareholder equity.
Lexicon Pharmaceuticals Inc (LXRX) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Lexicon Pharmaceuticals Inc. (LXRX) effectively leverages its workforce, generating an average of -$1171067.96 per employee. The company’s liquidity position is robust, with a Current Ratio of 4.16% and a Quick Ratio of 4.16%, indicating strong ability to cover short-term liabilities.
Earnings analysis for Lexicon Pharmaceuticals Inc [LXRX]
With the latest financial reports released by the company, Lexicon Pharmaceuticals Inc posted -0.18/share EPS, while the average EPS was predicted by analysts to be reported at -0.17/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.01. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for LXRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Lexicon Pharmaceuticals Inc go to 31.00%.
Insider trade positions for Lexicon Pharmaceuticals Inc [LXRX]
There are presently around $72.07%, or 72.93%% of LXRX stock, in the hands of institutional investors. The top three institutional holders of LXRX stocks are: ARTAL GROUP S.A. with ownership of 175.1 million shares, which is approximately 56.3318%. FMR LLC, holding 38.69 million shares of the stock with an approximate value of $$64.99 million in LXRX stocks shares; and FMR LLC, currently with $$16.62 million in LXRX stock with ownership which is approximately 3.1818%.
